Bella Thornton-Clark

Bella regularly advises companies ranging from early stage start-ups to late stage unicorns on a wide range of corporate matters. Bella started her career as a venture capital lawyer in San Francisco before moving to London. Her clients value her commercial insight into trends and norms in the Californian start-up market. Bella's practice is focused on technology start-ups with particular emphasis on consumer goods, SaaS, healthcare, and fintech.

Expertise

Rechtsgebiete und Gruppen

Venture Capital

Private Equity

M&A / Gesellschaftsrecht und Kapitalmarktrecht

Environmental, Social & Governance (ESG)

Corporate Venture Capital

Exit Strategien (Venture Capital)

Mitarbeiter- & Managementbeteiligung

Finanzierungsrunden (Seed-Finanzierungen & Wachstumsfinanzierungen)

Start-up Beratung

VC Fonds Beratung

M&A

Branchen

Technologie-, Medien & Kommunikationsrecht

Life Sciences & Healthcare

Fintech

Software

Biotechnologie

Over the past 10 years, we've built a trusted legal team in San Francisco, focused on technology, media and communciation, life sciences and healthcare, real estate, private wealth, and private equity. Supported by colleagues in the UK and Europe, we also offer deep expertise in M&A, international growth, commercial deals, and data privacy.

Find out more

CV

Since 2024 Senior Associate, Taylor Wessing

2022 - 2024 Associate, Taylor Wessing

2020 - 2022 Associate, Gunderson Dettmer, San Francisco

2019 - 2020 Associate, Kirkland & Ellis, San Francisco

2019 Admission to California Bar

2019 J.D. University of Texas School of Law

Karriere

Since 2024 Senior Associate, Taylor Wessing

2022 - 2024 Associate, Taylor Wessing

2020 - 2022 Associate, Gunderson Dettmer, San Francisco

2019 - 2020 Associate, Kirkland & Ellis, San Francisco

Ausbildung

2019 Admission to California Bar

2019 J.D. University of Texas School of Law

Experience

Blue Earth Therapeutics on the closing of US$76.5 million Series A funding

We have advised Blue Earth Therapeutics and its management on the closing of US$76.5 million Series A funding. The new funding comes from a broad spectrum of experienced biotech investors and enables Blue Earth Therapeutics to further advance its clinical stage prostate-specific membrane antigen-targeted radioligand therapies.

Press release

Ross McNaughton

Bella Thornton-Clark

Advising gene therapy company AlveoGene on its complex spinout and launch investment

We have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.

Press release

Colin McCall

Ross McNaughton

Bella Thornton-Clark